10 months ago
Immediate News Release – Convicted by the same judge as Julian Assange,
Cancer Cure Creator David Noakes is Being Expedited to France
The jailed distributor of potential cancer cure GcMAF, David Noakes, is in the process of being swiftly extradited to France.
To the horror of his legal team, it was announced Friday Mr. Noakes is to be moved despite current ill health and the COVID19 pandemic.
Noakes of Waldershare in Kent, who made and distributed GcMAF globally from the UK, was jailed in November 2018 by one of the same judges who convicted Julian Assange, Judge Deborah Frances Taylor, who strangely abandoned the case after Noakes’ legal representative challenged a number of legal and procedural errors.
Post COVID19, Noakes has found sudden and growing support in large numbers worldwide – particularly in the US – thanks to increasing suspicion from the general public in reference to big pharma and the monopoly on drug administrations and their authority, with many drawing parallels between Noakes’ case and GcMAF to the “unproven” coronavirus ‘miracle cure’ drug made famous by Donald Trump, Hydroxychloroquine, distributed by Canadian pharmaceutical billionaire couple Barry and Honey Sherman who were both murdered in December 2017.
According to his Noakes’ supporters, scientific evidence clearly shows that GcMAF is potentially the most effective cancer treatment ever discovered.
Given sentencing Judge Nicholas Lorraine-Smith himself stating: “It is not GcMAF that is on trial”, questions have swirled around the involvement of big pharma within the outcome of Noakes’ investigation, incarceration, and now his impending deportation.
The charges were brought against Mr. Noakes, his team of research scientists, doctors, nurses, and medical researchers at Immuno-Biotech, by the UK MHRA despite GcMAF having been instrumental in successfully treating people who had been written off by the medical profession.
In response to the Access To Medical Treatments Act (Innovations) 2016, the MHRA issued guidance states that prescribers “should first consider using a licensed medicine where possible; if that is not possible, then a licensed medicine off-label should be used, and only if neither of these are available should an unlicensed medicine be considered”.
Of note, every patient selected for the GcMAF UK trials by Immuno Biotech had exhausted all licensed treatment options and in each case treatment had failed, therefore providing them with GcMAF was both legal and within the MHRA guidelines.
Further, the clearly stated purpose of the Act is to allow responsible doctors to prescribe off label (using licensed drugs for innovative purposes) or unlicensed drugs, such as GcMAF if it is considered by the prescribing Doctor to be beneficial. To that end, all Immuno Biotech GcMAF treatments were prescribed by qualified Doctors who thought to prescribe it would be beneficial.
Adding to the already murky waters, directly after being accused of malpractice by Noakes’ team, Judge Nicholas Loraine Smith (Southwark Crown Court) mysteriously decided to take early retirement only two weeks ago.